

Grand Valley State University
ScholarWorks@GVSU

Masters Theses


Graduate Research and Creative Practice

8-2020

From the Dinner Pot to Smoking Pot; How a Better Understanding of Cannabidiol in Crayfish could Alleviate Anxiety and Modulate Hunger

Christopher Michael Timmer
Grand Valley State University

Follow this and additional works at: <https://scholarworks.gvsu.edu/theses>

 Part of the [Biochemical Phenomena, Metabolism, and Nutrition Commons](#), and the [Biology Commons](#)

ScholarWorks Citation

Timmer, Christopher Michael, "From the Dinner Pot to Smoking Pot; How a Better Understanding of Cannabidiol in Crayfish could Alleviate Anxiety and Modulate Hunger" (2020). *Masters Theses*. 985.
<https://scholarworks.gvsu.edu/theses/985>

This Thesis is brought to you for free and open access by the Graduate Research and Creative Practice at ScholarWorks@GVSU. It has been accepted for inclusion in Masters Theses by an authorized administrator of ScholarWorks@GVSU. For more information, please contact scholarworks@gvsu.edu.

From the Dinner Pot to Smoking Pot; How a Better Understanding of Cannabidiol in Crayfish
could Alleviate Anxiety and Modulate Hunger

Christopher Michael Timmer

A Thesis Submitted to the Graduate Faculty of
GRAND VALLEY STATE UNIVERSITY

In

Partial Fulfillment of the Requirements

For the Degree of

Masters of Health Sciences

Biomedical Sciences Department

August 2020

Contents

Abstract.....	7
Hypothesis.....	8
Specific Aims.....	8
Introduction and Background	11
Anxiety Economics and Prevalence.....	11
Anxiety Pathology	12
Anxiolytic Medication and Side Effects	14
CBD and Endocannabinoids	17
Crayfish Physiological Model.....	19
Methods and Materials.....	22
Animals.....	22
Drug Selection	22
Drug administration and preparation	23
Behavior observations.....	23
Aim 1: Aggressive interaction protocol	23
Aim 1: Fight Analysis.....	23
Aim 2: Hunger and food-seeking.....	25
Aim 3: Motility	25
Results.....	26
Statistics.....	26
Motility	26
Fights	30
Hunger	47
Discussion.....	52
Motility	52
Fights	53
Hunger	55
Conclusion	56
References.....	57

List of Tables

Table 1 Crayfish Ethogram Codes (Used to score fight intensity levels)	24
Table 2 Descriptive Statistics for Motility	26
Table 3 Motility Statistics Summary	29
Table 4 Independent Samples Test For Percent Time Resting and Moving	29
Table 5 Descriptive Statistics for paired fight analysis.....	31
Table 6 Descriptive For Fight Analysis based on Compound	34
Table 7 ANOVA Significance for Fight Analysis based on Compound	35
Table 8 Multiple Comparisons for Fight Analysis based on Compound.....	36
Table 9 Case Processing Summary for Fight Analysis based on Compound Used.....	37
Table 10 Case Processing Summary for Fight Analysis when Examined by Fight Compound Pair Type	37
Table 11 Descriptive Statistics for Fight Analysis by Compound Pair Type	37
Table 12 ANOVA Results for Fights based on Compound Pair Type	42
Table 13 Multiple Comparisons for Fights based on Compound Pair Type.....	42
Table 14 Case Processing Summary for Percent Food Consumed by Compound and Concentration	47
Table 15 Descriptive Statistics for Mean Percent Food Consumed by Compound and Concentration.....	48
Table 16 Multiple Comparisons For Mean Percent of Food Consumed based on Compound Used.....	50

List of Figures

Figure 1 Mean Percent of Time Resting Based on Compound.....	28
Figure 2 Mean Percent of Time Spent Moving Based on Compound	28
Figure 3 Mean Fight Score by Ethogram based on Compound Used.....	34
Figure 4 Mean Percent of Time Fighting based on Compound Used.....	34
Figure 5 Mean Fight Score by Ethogram Based on Compound Pair Type.....	41
Figure 6 Mean Percent Time Fighting based on Compound Pair Type.....	41
Figure 7 Non-parametric Analysis of Time Spent Fighting.....	44
Figure 8 Non-parametric Boxplots for Pair-based Time Spent Fighting	44
Figure 9 Pairwise Comparisons of Fight Times and Hypothesis Table for Non-parametric Testing	45
Figure 10 Non-Parametric Box Plots and Summary for Fight Analysis based on Ethogram Score	46
Figure 11 Mean Percent Food Consumed base on Compound and Concentration Injected.....	50
Figure 12 Means Plot for Percent Food Consumed based on Compound and Concentration	51

List of Abbreviations

Abbreviation	Definition
5-HT, 5HT	Serotonin
CBD	Cannabidiol
DALY	Disability-Adjusted Life Year
EPSP	Excitatory Postsynaptic Potential
GAD	General Anxiety Disorder
LG	Lateral Giant (Neuron)
LSAS	Liebowitz Social Anxiety Scale
NE	Norepinephrine
NMJ	Neuromuscular Junction
PET	Positron Emission Tomography
PTSD	Post-Traumatic Stress Disorder
SAD	Social Anxiety Disorder
SNP	Simple Nucleotide Polymorphism
SSRIs	Selective Serotonin Reuptake Inhibitors
	Treatment Satisfaction Questionnaire for
TSQM	Medications
VH	Van Harreveld (Saline Solution)

Abstract

Anxiety affects approximately 1/3 of the US population and presents in many different forms, ranging from social to panic disorders. It also presents with high comorbidity for other mental disorders. One treatment is Selective Serotonin Reuptake Inhibitors (SSRIs) which allow for increased activation of serotonin (5-HT) receptors. SSRIs come with an extensive list of side effects, which can fail to maintain quality of life. Cannabidiol (CBD) is a cannabis derived compound which has been shown to decrease anxiety by activation of multiple subtype 5-HT amine receptors. CBD has few side effects, is not psychoactive, and exhibits anti-psychotic properties. The current understanding of CBD's mechanisms is limited specifically in invertebrates, where to date limited published research involves behavior and cannabinoids. Decapod crustaceans, such as crayfish, have emerged as a novel approach to studying drugs of abuse. Within the neural structures of the crayfish tails are 5-HT receptors that control tail-flips, a withdraw reflex when placed into a fight. Serotonin has also been linked to aggression and decision making for engaging in fights with other crayfish. Additionally, evidence currently suggests CB1 receptors are present at neuromuscular junctions (NMJ) and may have an impact on motility. For this thesis, crayfish were administered either CBD, 5-HT, or a vehicle control. Analysis of motility by percent of time moving or rest, amount of food consumed, and aggression in paired fights were conducted. No statistical significance was found for CBD influencing motility and hunger. However, the duration of fights significantly increased when injected with CBD and when paired with 5-HT injected crayfish. This evidence supports the main hypothesis that CBD increases serotonin receptor activity in crayfish as seen with SSRIs, thus could be of use in treating anxiety.

Hypothesis

The primary goal of this study was to provide evidence that CBD increases 5-HT receptor activity in crayfish tail neural tissue resulting in decreased tail-flip behavior. This same escape reflex has been shown to be decreased with use of SSRIs. Additionally, there are serotonin receptors lining the digestive system in crayfish that could be influenced by CBD. Finally, cannabinoid receptors have been found in the NMJ of crayfish thus suggesting that CBD may increase or decrease the motility of crayfish. The ultimate question at hand was if CBD is an adequate candidate for replacing SSRIs when gauged by serotonin activation in crayfish. Hunger and motility behaviors could also be changed by CBD and were thus explored.

Specific Aims

The most prevalent mental disorder in the US is anxiety, affecting 33.7% of the population at one point in their life. Generalized Anxiety Disorders (GAD), Social Anxiety Disorders (SAD), agoraphobias, panic disorders, and specific phobias make up what is generalized into anxiety. One concerning component of anxiety is the high comorbidity for other mental disorders. One method of treatment is Selective Serotonin Reuptake Inhibitors (SSRIs) which allow for increased activation of serotonin (5-HT) receptors. However, SSRIs come with an extensive list of side effects, some of which fail to maintain quality of life. Cannabidiol (CBD) is a cannabis derived compound which has been shown to decrease anxiety by activation of multiple subtype 5-HT amine receptors. Unlike SSRIs, CBD has few side effects. Additionally, it is not psychoactive and even has anti-psychotic properties. CB1 receptors can have bound CBD where it acts as an allosteric inhibitor of anandamide resulting in decreased drive for food. The current understanding of CBD's mechanisms is limited specifically in invertebrates where to date no published articles involve behavior and cannabinoids. Decapod

crustaceans, specifically crayfish, have emerged as a novel approach to studying drugs of abuse. Crayfish tails contain 5-HT receptors that control tail-flips, a withdrawal reflex to rapidly retreat. One specific serotonin linked behavior is aggression and decision making for engaging in fights with other crayfish. Additionally, evidence currently suggests CB1 receptors are present at neuromuscular junctions (NMJ) and may have an impact on motility. Preliminary studies were conducted to evaluate any change CBD has on the NMJ.

Aim 1: Observe and measure fights of equal sized crayfish via time spent engaged in aggressive behavior and fight duration. Crayfish administered with CBD and 5-HT or agonist will be paired by weight and placed into fights. The correlation between time and behavior will indicate how CBD and SSRIs compare within simple neural structures.

Aim 2: Observe and measure amount of food consumed. CBD and 5-HT or agonist will be administered. The quantitative consumption will indicate how CBD and SSRI compare on hunger.

Aim 3: Examine motility by time spent resting verses moving. CBD and saline control injections will be completed in crayfish. The resulting ability to move will be examined to determine if CBD has an influence on the neuromuscular junction.

CBD has been shown to influence the same receptors as serotonin that produce anxiety. Over a third of the population will experience an anxiety disorder. The current SSRIs used to return functionality to impacted individual leaves them exposed to equally unpleasant side effects. A new treatment may be found through CBD which offers potentially comparable relief without the

tradeoff of current medications. Treatment with CBD in crayfish should produce similar results of those injected with serotonin.

Introduction and Background

Anxiety Economics and Prevalence

The economic and epidemiological survey of mental disorder can best be described as common and costly. Mental illnesses, including anxiety are ranked in the top five global exorbitant conditions. The out of pocket costs for treatment were found to be 23.1% in 1996, and 25.0% in 2006. In addition, mental disorders saw a rise in total costs from \$35.2 billion to \$57.5 billion between 1996 to 2006. This correlated with the total number of cases increasing from 19.3 million to 36.2 million in the same time frame(1). Estimates in the year 2010 indicate that the cost is now around US \$2.5 trillion and will increase to \$6.0 trillion by 2030. In addition to direct costs of treatment for an illness one must consider the indirect expenses of an illness such as the Disability-Adjusted Life Year (DALY). Mental illnesses have a larger impact on the DALY then other chronic conditions such as diabetes (2,3). Despite having high cost and prevalence associated with mental disorders, the general public places higher budgetary priority on somatic illness such as cancer and diabetes (4). Multiple economic and personal burdens are associated with mental disorders and there is a need for more awareness (5). The most prevalent mental disorder in the US was found to be anxiety of any type ranging from 18.0% (6) to 38.0% (7). This includes general anxiety disorders (GAD), social or separation anxiety disorders (SAD), agoraphobias, specific phobias, social phobias, panic disorders, and post-traumatic stress disorders (PTSD). Anxiety was found to be comorbid with other mental illnesses like depression and bipolar disorders as well as physical disabilities such as asthma or diabetes (3,8).

Anxiety Pathology

The pathological cause of mental illness is a complex network of disruptions in normal brain activity. One such area of interest for depression and anxiety is the group of serotonin amine receptor family along with norepinephrine (NE) turnover (Reviewed by Ressler and Nemeroff 2000). 5-HT receptors are found throughout the central nervous system such as the pathways of the basal ganglia, hippocampus, hypothalamus and spinal cord through the dorsal raphe. Serotonin receptors include 12 different subtypes, such as the 5-HT_{1A}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, and 5-HT₄ families (10–12). For this study, the action of the 5-HT_{1A} receptor as related to anxiety was investigated. 5-HT_{1A} abnormalities have been well documented for their presence in patients with depression and anxiety. One example is the analysis of suicide victim who experienced depression. The dysregulation of 5-HT_{1A} in the victims indicated a direct correlation to amine-based receptor malfunctions and decreased receptor prevalence. In addition, positron emission tomography (PET) of comorbid patients for panic disorders and depression revealed significant alterations in the 5-HT_{1A} receptor prevalence compared to controls (13). A similar PET scan study using males with SAD indicated a decreased binding potential for the 5-HT_{1A} receptors (14). One explanation for the dysregulation could be genetic predisposition. Genetic examination concluded that up regulation of auto receptors within the dorsal raphe from simple nucleotide polymorphism (SNP) could result in the decreased firing rate (15,16). Evidence also suggests that 5-HT_{1A} plays a key role in development of emotional behaviors. This was shown with fine tuning of the 5-HT_{1A} heteroreceptors and auto receptors using knockout mice models (16–18). To summarize, PET scans, genetic predisposition, pharmacological studies and post mortem analysis all concluded that 5-HT_{1A} has a crucial role in anxiety. This is postulated to be due to a decreased binding potential in the pathological state for anxiety and depression (19). But

the actual role of serotonin and 5-HT_{1A} activation is still under debate. Serotonin dysregulation has also been linked to neurodegenerative disease like Parkinson's where it presents with depression (11) and tremors (20). The current treatment for pathological 5-HT receptor abnormalities is with Selective Serotonin Reuptake Inhibitors (SSRIs). The current theory for SSRI treatment is that additional 5-HT is available for activating 5-HT_{1A}. This results in a less pathological state for treatment of anxiety and depression disorders (21).

Anxiolytic Medication and Side Effects

One option for treatment of anxiety disorders is use of SSRI compounds, such as paroxetine, fluvoxamine, sertraline, fluoxetine, and escitalopram. SSRIs have been shown to be effective in both anxiety and depression and are often utilized when disease states presents individually or in comorbidity (22). Early studies on paroxetine, fluvoxamine, sertraline and fluoxetine and citalopram concluded the statistical significance in decreased social anxiety based on the Liebowitz Social Anxiety Scale (LSAS)(23), while later summaries of the studies show additional evidence that included escitalopram (24). The primary mode of action of SSRIs is to produce additional synaptic 5-HT, thus increasing the activation of the serotonin receptors (25). However, the hypothesized activation of various subtypes of receptors in the body could be the source of multiple side effects (10). These include alterations in sexual function leading to delayed ejaculation, decreased libido, and anorgasmia in up to 60% of patients. Gastrointestinal systems can include nausea, diarrhea, dry mouth, constipation, and anorexia. The central nervous system can be impacted to produce anxiety, insomnia, sedation, and nightmares. This can include extrapyramidal symptoms like akathisia (constant movement or motor restlessness). Approximately twenty five percent of patients on SSRIs have reported insomnia or somnolence. Additional adverse effects include bleeding by inhibition of platelet function resulting in bruising and epistaxis. Hyponatremia can occur but is rare. Serotonin syndrome can arise from hyperstimulation of the 5-HT receptors if SSRIs are used with monoamine oxidase inhibitors, pentazocine or L-tryptophan. This overstimulation leads to nausea, diarrhea, restlessness, extreme agitation, hyperreflexia, autonomic instability, myoclonus, hyperthermia, rigidity, delirium, seizures and status epilepticus. In extreme instances this can lead to cardiovascular collapse, coma and death. The withdrawal from use of SSRIs can lead to discontinuation

syndrome, characterized by dizziness, nausea, weakness, insomnia, anxiety, irritability and headache. These symptoms dissipated over time, usually a few weeks. Tapering off SSRIs before complete discontinuation helps alleviate withdrawal symptoms(26). The prevalence of these side effects is well documented. In one cohort study of 584 patients actively on SSRIs the top most side effects included sleepiness during the day (21%), dry mouth (22%), profuse sweating (20%), sexual dysfunction (19%), dizziness (12%). Sleepiness, restlessness, muscle spasm, twitching, nausea, constipation, and diarrhea were reported below at or below 10% of cases (27). An additional study conducted using a drug safety monitoring service utilized a Treatment Satisfaction Questionnaire for Medications (TSQM) to collect patient data for those on SSRIs of citalopram, escitalopram, fluoxetine, paroxetine, and sertraline. Of the approximate 700 patients surveyed, 38% indicated that they experienced one or more side effect, while 229 listed the adverse effect of sexual dysfunction, sleepiness, and weight gain as the most crucial. The symptoms were also ranked by how bothersome they presented which indicated that 7% found them extremely bothersome, 19% very bothersome, 40% somewhat bothersome, 29% little bothersome, and 5% not at all bothersome (28). One of the earlier studies on SSRI use for 75-105 days examined 401 patients via phone interviews to conclude that 344 (86%) reported experience at a minimum one side effect, while 219 (55%) indicated that at least 1 or more of the side effects was bothersome. Sexual dysfunction and drowsiness tied at 17% for most common bothersome. Those who experienced a side effect in the first two weeks indicated that at the end of the study blurred vision (85%) and sexual dysfunction (83%) remained. These results show how the bothersome side effects are persistent after three months of treatment (29). One hypothesis for the range of side effects centers on SSRIs causing inhibition of dopamine neurotransmitter release either by direct interaction or by modulation of serotonin receptors for

dopamine. This was concluded by examination of clinical reports on side effect occurrences and instances where stimulation of dopamine releasing treatments counteracted SSRI side effects (30). Due to the high out-of-pocket cost of treatment, increased prevalence, and well documented side effect, alternative treatments for anxiety have been pursued. One such treatment with potential anxiolytic effect is cannabidiol (CBD), a phytocannabinoid derived the plant cannabis sativa (31).

CBD and Endocannabinoids

Cannabidiol or CBD has emerged as a novel compound for its various interaction with multiple receptors in the human body. These receptors include CB1, CB2, PPAR γ , and 5-HT1. The correlated physiological response is weight loss, insulin sensitivity, reduced atherosclerosis, and anxiolysis respectively. Additionally, CBD has been found to lower high glucose levels and cell inflammation due to its antioxidant, anti-inflammatory properties (32), relief of A β -Induced neuroinflammation to promote hippocampal neurogenesis as related to Alzheimer's disease (33), protective properties against myocardial ischemic reperfusion injuries (34), and treatment potential for acute and anticipatory nausea (35). Cannabinoids in medicine is not unheard as documentation indicates that cannabis was used in China over a thousand of years ago (36). The recent rediscovery of its benefits has led to a surge into marijuana medical research. Over the past thirty years extensive research has been done on cannabis receptors within the human body. This led to discovery of endogenous cannabinoids used in the human body that specifically act on the hunger drive mechanism (37). The safety limit for CBD was found through animal models and human trials to be safe at elevated levels beyond the useful range (38). CBD has long been known to counteract the effects of Δ 9-THC, the active component of cannabis that produces the sensation of feeling high as well as paranoia and anxiety. This was shown in a study that used human subjects who consumed both compounds and were surveyed for anxiety and paranoia (39). Extending past this, CBD has been shown to be non-psychoactive and even display anti-psychotic properties through both human trials and animal studies (40). Investigation into the antianxiety effects of CBD have been promising. The use SSRIs was compared against CBD to determine the potency of anxiolysis. Elevated plus-maze evaluations of anxiety with CBD in rats concluded with increased time spent on the open arms (41). Similarly, Vogel conflict tests with

rats came to the same conclusion that CBD had alleviated anxiety behavior as observed by increased punished licks (42). The use of CBD in humans produced a U-shaped curve for decreased anxiety similar to those found with SSRIs when subjects were placed into public speaking scenarios (43). In addition, a dampened emotional response was not seen with treatment of CBD. A study of 38 healthy individuals concluded that CBD did not numb emotional responses to negative social stimuli nor social rejection which indicates that behavior changes are not seen with use of CBD (44). The specific physiological reason that CBD has antianxiety properties has been thought to be from the effect on 5-HT receptors. This was demonstrated by administrations of CBD to the dorsolateral periaqueductal of rats followed by observations on elevated plus-maze and Vogel conflict test. Use of an antagonist to 5-HT_{1a} stopped the effects from the CBD(45). Alternatively, the co-presence of 5-HT_{3a} and CB1 in the interneurons of the hippocampus and dentate gyrus was found through situ hybridization histochemistry and could lead to avenues for research. Additional studies are required to further determine the extent that these receptors play on anxiety (46). To better understand the social and behavior effects of CBD examination in other biological systems could provide further insight. A recent approach to pharmacology has been to use invertebrates as models for physiology. Recent studies have shown evidence for CB1 receptors at the neuromuscular junction(NMJ) of crayfish from antibody-selective immunofluorescent staining microscopy (47) and pharmacological activation measured via excitatory post synaptic potentials electrical amplitude (48). In addition to the cannabinoid receptors, 5-HT receptors are also found within crayfish. The approach to using SSRIs within crayfish has been shown to dramatically change the outcome of their behaviors as serotonin receptors play a crucial role in aggression and social ranking.

Crayfish Physiological Model

Decapod crustaceans, specifically crayfish, have emerged as a novel physiological model for studying pharmacological properties. Some of the most dramatic examples include studies involving drugs of abuse where the behavior changes were most notable. (49–52). Crayfish have been found to express serotonin and serotonin receptors within various tissues (53,54). Genetic studies concluded that 5-HT_{1A} and 5-HT₂ were conserved compared with *Procambarus clarkii* (southern swamp crayfish) and *Panulirus interruptus* (lobster) in structure and function (55). Direct injections of serotonin into the brains of crayfish induced an avoidance behavior and decreased movement when placed into a light-dark maze (56). This provides insight into how 5-HT plays a role in the CNS of crayfish and produces anxiety-like behaviors. However, within the peripheral nervous system the effects of serotonin are vastly different. Serotonin has been found to alter aggressive behaviors and cause changes in social ranking (57). This change is due to unidentified subtype receptors being found within the tail neural circuits that control tail-flip escape behavior (58). Specifically, the Lateral Giant (LG) neuron receives input from mechanosensory of the abdomen (59). With the use of the pharmacological 5-HT neurotoxin 5,7-Dihydroxytryptamine the LG neuron was shown to be directly modulated by 5-HT (60). The excitatory postsynaptic potential (EPSP) for the LG neuron has been shown to be inhibited by excessive serotonin in both monosynaptic(α) and di-synaptic(β) connections (61,62). Serotonin has also been shown to depolarize the LG neuron allowing for less resistance to distal dendrites (63). A study conducted using 5-HT_{1A} and 5-HT₂ receptor agonists, 1-(3-chlorophenyl)piperazine dichloride (m-CPP Cl₂) and α -methylserotonin maleate (α -CH₃ 5-HT maleate) respectively, concluded that social isolation, subordination and dominance played a key role in how the EPSP changes from serotonin. The specific receptor subtypes identified from the study

were 5-HT₁ and 5-HT₂ like receptors that act in inhibition and excitation, respectively, when serotonin is present (64). With the connection that tail flip behavior was associated with 5-HT, the next logical step examined if SSRIs could decrease the retreating muscular reflex from the LG nerve. Injections of 5-HT directly into equally sized crayfish increased their fighting durations and intensity favoring aggression. Preliminary studies using acute injects of fluoxetine (Prozac) indicated that SSRIs had negligible behavioral changes, but this was expected as with humans the same result have been found. Notable changes with SSRIs require extended treatment times (65). Additional studies with fluoxetine postulated that during elevated levels serotonin is taken up by the LG neuron and released during times of fights. This would account for the fact the various concentrations of 5-HT change fight characteristics but the use of acute SSRIs had little to no effect (66). However, acute use of fluoxetine was shown to increase the amplitude of the EPSP at the neuromuscular junction indicating an excitatory effect, while chronic use had no effect. This was postulated to be caused by changes made to glutamate neurotransmitter release, potentially causing reuptake inhibition as with serotonin (67). This would account for the fact that other naturally occurring anxiolytics have been shown to play a role in glutamate related neural activity. One such example is *Hypericum perforatum* from St John's Wort(68). This would also account for the observed action of endocannabinoids on the crayfish neuromuscular junction. Initial use of a cannabinoid like pharmacological agent indicated a glutamatergic decrease in EPSP amplitude in crayfish at the NMJ (48), while this was later identified as CB1 receptors from immunofluorescence and microscopy (47). Further studies using CB1 receptor agonist found that the EPSP was decreased at the NMJ in crayfish (69). Currently, there no published studies that look at crayfish behavior with injections of endocannabinoids, including cannabidiol. Since CBD has been shown to act as an allosteric

inhibitor of CB1 receptors this could play a role in motility and was addressed in this study as a potential confounding variable for behavior analysis. Initial trials were conducted to measure the degree that CBD can alter movement.

Methods and Materials

Animals

Male and female intermolt (form I) crayfish, *Faxonius propinquus*, with fully intact appendages were socially and physically isolated in a flow-through holding tank. Crayfish will also be kept at a constant temperature (23°C) and light:dark cycle (14hr:10hr) and crayfish were isolated for a minimum of one week prior to experimentation to reduce the effects of prior social experience for fight trial. Crayfish were size-matched within 90% for carapace length (from rostrum to beginning of abdomen) and weight to reduce size influences on fights (70). Each crayfish, regardless of treatment, were used only once during this study. Crayfish were marked with white correction fluid on the carapace for later identification during behavioral analysis for fights (Bergman lab). For hunger analysis crayfish were deprived of food for a minimum of two days prior to study. Crayfish used for the motility trials were not isolated or starved prior to injections.

Drug Selection

To determine the effects of CBD on aggression, food seeking, and neural activity the use of Van Harreveld's (VH) saline solution was employed as a vehicle control. The standard control was 5-HT. For all trials 5-HT was injected at a concentration of 5ug/g, a concentration sufficient to cause postural changes (71). The control (Van Harreveld's solution) consisted of 12 g of NaCl, 0.4 g of KCl, 2 g of CaCl₂, 0.5 g of MgCl₂, 0.2 g of NaHCO₃ per 1 L of H₂O with a pH of 7.4 (72). CBD trials for hunger were administered at a dose of 2.0 µg/g, 5 µg/g, and 10 µg/g. For fight analysis only 2.0 µg/g of CBD was injected, and 10 µg/g for motility studies. These concentration were chosen from previous rodent studies (42).

Drug administration and preparation

Crayfish weight was used to determine proper amount of drug required for each animal. Crayfish were then randomly assigned to an experimental group. Syringe injections were completed through the dorsal portion of the tail between abdomen plates into the cardiac sinus. A petroleum jelly (Vaseline) was used to help seal the wound and prevent leakage. Crayfish which weighted above 5g received injections of 1.0 ml while smaller crayfish received 0.5 ml injects. The compound concentration injected relative to the size remained the same. For the CBD injections, initial stock of 1.0mg/ml ampule suspended in methanol was dried over air until CBD globules remained. The CBD was reconstituted with VH Saline at a concentration of 0.2mg/ml by heating to 70 degrees Celsius while stirring with a magnetic stir bar.

Behavior observations

Aim 1: Aggressive interaction protocol

For fight experiments, crayfish were tested in pairs consisting of animals that differed by no more than 10% in body weight and 10% in carapace length and were the same sex. After injection of solution the crayfish were placed in the separate compartments of the fight arena and allowed to acclimate for 15 min. The fight arena is made of Plexiglas (20 × 20 × 14 cm) and is divided into halves, separated by opaque retractable walls. The arena holds 10L of dechlorinated water (filled to a depth of 4 cm from the top of the tank). After acclimation, the divider was removed, allowing two crayfish to interact. An opaque curtain surrounds the fight tank to prevent external distractions. The interacting animals were video recorded for 15 to 30 minutes. After the fight the crayfish were returned to isolation tanks and not reused in future trials (Bergman lab).

Aim 1: Fight Analysis

All fights were digitally recorded from a camera positioned one meter above the test arena. For each encounter, recordings of the winners and losers of each fight was determined as

well as the temporal mechanics of the fight (Table 1). Temporal mechanics include time to different fight intensities and duration of the initial encounter. All interactions were analyzed by examining the behavior of both participants while each individual receives a unique ethogram value. In addition, the percent of time spent in interactions was analyzed.

The identities of initiating and winning animals are to be recorded for each interaction. The crayfish that first engages an opponent with either a meral spread (Claws raised) or physically contact was deemed the initiator. The dominant crayfish is determined by the animal that pursues its opponent (i.e. the loser) as it retreats or tail-flips away, or if the two crayfish adopt body postures indicating dominance. Dominant crayfish tend to exhibit high body postures, extended tails and pointing or raised claws, whereas subordinate crayfish tend to exhibit lowered body position and tails curled under the body (70). Prior studies indicate that 5-HT can induce an “aggressive posture” that resembles a meral spread – a common display of dominant animals (73). Yet Tierney and Mangiamele (2001) note that the aggressive meral spread posture could involve either an elevated or depressed posture, so when observing postural effects alone status roles will not necessarily be assigned.

Table 1: Crayfish Ethogram Codes (Used to score fight intensity levels)

Intensity Level	Description
-2	Tailflip away from opponent or fast retreat
-1	Retreat by slowly backing away from opponent
0	Visually ignore opponent with no response or threat display
1	Approach without a threat display; claws raised
2	Initial claw use by boxing, pushing and/or touching
3	Active claw use by grabbing and/or holding opponent

Aim 2: Hunger and food-seeking

To determine the effects CBD has on food-seeking behavior and hunger, each pre-starved crayfish was injected with 2ug/g, 5 ug/g, 10ug/g CBD, VH saline control or 5ug/g 5-HT and placed into a small isolated tank approximately 10 inches by 10 inches and allowed five minutes to acclimate. The weight of a small portion of a tilapia filet was taken prior to being placed into the insolation tank. After 10 minutes, if the fila piece remained intact it was removed, dried, and weighted again. The difference in initial and final weights were used a percent indicator for how much was consumed.

Aim 3: Motility

To assess the degree that CBD plays on the NMJ, crayfish were injected with saline control Van Harreveld's solution or 10ug/g CBD and placed an isolation tank with opaque curtain to decrease external distractions. The animals were video recorded to observed total distance explored in the tank for the initial 12 minutes. The crayfish was then returned to isolation tanks and not reused for further trials.

Results

Statistics

All statistical analysis was completed using SPSS 25 provided by Grand Valley State University. A significance level of 0.05 was used for hypothesis testing outcomes.

Motility

The descriptive statistics for the motility trials can be found in Table 2. From this data Figure 1 displays the mean percent of time resting while Figure 2 is the mean percent of time moving. Table 3 displays the group statistics for number of samples based on compound. Note how the VH saline controls had a large standard deviation compared to the CBD. These results were analyses with a two-sample T-test of means (Table 4) which yielded no significant difference. A Mann-Whitney U Test was performed and no significance was found using a non-parametric testing method as well.

Table 2 Descriptive Statistics for Motility

	Compound		Statistic	Std. Error
Percent Time Resting	Blank VH Saline	Mean	50.5000	11.01741
		95% Confidence Interval for		
		Lower Bound	22.1788	
		Upper Bound	78.8212	
		5% Trimmed Mean	50.2037	
		Median	48.5000	
		Variance	728.300	
		Std. Deviation	26.98703	
		Minimum	20.67	
		Maximum	85.67	
		Range	65.00	
		Interquartile Range	51.50	
		Skewness	.188	.845
		Kurtosis	-2.258	1.741
		10 ug/mg CBD	Mean	52.0202
		Lower Bound	44.0799	

		95% Confidence Interval for Upper Bound	59.9604	
		Mean		
		5% Trimmed Mean	52.3743	
		Median	52.8333	
		Variance	90.205	
		Std. Deviation	9.49763	
		Minimum	31.67	
		Maximum	66.00	
		Range	34.33	
		Interquartile Range	3.95	
		Skewness	-1.254	.752
		Kurtosis	3.948	1.481
Percent Time Moving	Blank VH Saline	Mean	49.5000	11.01741
		95% Confidence Interval for Lower Bound	21.1788	
		Mean Upper Bound	77.8212	
		5% Trimmed Mean	49.7963	
		Median	51.5000	
		Variance	728.300	
		Std. Deviation	26.98703	
		Minimum	14.33	
		Maximum	79.33	
		Range	65.00	
		Interquartile Range	51.50	
		Skewness	-.188	.845
		Kurtosis	-2.258	1.741
	10 ug/mg CBD	Mean	47.9798	3.35792
		95% Confidence Interval for Lower Bound	40.0396	
		Mean Upper Bound	55.9201	
		5% Trimmed Mean	47.6257	
		Median	47.1667	
		Variance	90.205	
		Std. Deviation	9.49763	
		Minimum	34.00	
		Maximum	68.33	
		Range	34.33	
		Interquartile Range	3.95	
		Skewness	1.254	.752
		Kurtosis	3.948	1.481

Figure 1 Mean Percent of Time Resting Based on Compound




Figure 2 Mean Percent of Time Spent Moving Based on Compound




Table 3 Motility Statistics Summary

	Compound	N	Mean	Std. Deviation	Std. Error Mean
Percent Time Resting	Blank VH Saline	6	50.5000	26.98703	11.01741
	10 ug/mg CBD	8	52.0202	9.49763	3.35792
Percent Time Moving	Blank VH Saline	6	49.5000	26.98703	11.01741
	10 ug/mg CBD	8	47.9798	9.49763	3.35792

Table 4 Independent Samples Test For Percent Time Resting and Moving

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
Percent Time Resting	Equal variances assumed	17.580	.001	-.149	12	.884	-1.52016	10.19098	-23.72440	20.68408
	Equal variances not assumed			-.132	5.935	.899	-1.52016	11.51777	-29.77754	26.73722
Percent Time Moving	Equal variances assumed	17.580	.001	.149	12	.884	1.52016	10.19098	-20.68408	23.72440
	Equal variances not assumed			.132	5.935	.899	1.52016	11.51777	-26.73722	29.77754

Fights

The descriptive statistics can be found in Table 5 for the two areas of interest for fight analysis. The values analyzed included the mean fight score by ethogram, and the percent of time spent fighting. Boxplots were generated for the mean fight scores based on compound (Figure 3) and the mean percent of time spent fighting by compound injected (Figure 4). Table 6 redisplay the descriptive statistics for the ANOVA analysis completed in Table 7. Significance was found with a pvalue of 0.004 for percent of time fighting being different between injection types. No significance was found for total fights in the first twelve minutes(additional area investigated) and mean fight ethogram score. Table 8 displays the post-hoc analysis which indicates that significance found for mean percent of time fighting was higher for both the CBD and 5HT when compared to Blank VH saline control injections. All other areas held no significance. A summary of the number of trials completed for analysis was generated(Table 9). Additional analysis was completed to examine how the effects of pair-wise matching by compound injected might change the means. Table 10 includes the number of samples used while Table 11 details the descriptive statistics for the pair-wise analysis. Boxplots for Mean Fight Score(Figure 5) showed less variance as compared to the Mean Percent Time Fighting(Figure 6) based on the compound pairing type specifically for the CBD-5-HT pairings. ANOVA analysis was completed (Table 12). Significance was found that Mean Percent of Time Fighting was not the same for all groups analyzed. Post-Hoc analysis in Table 13 shows that the CBD-5HT injections pairs had significantly longer fight times compared to Blank-Blank, Blank-CBD, and Blank-5HT injection pairings. Due to the low number of subjects a non-parametric test was conducted and yielded similar results to the ANOVA analysis. Figure 7 displays the hypothesis test summary for pair-wise analysis of Mean Fight Score and Mean Percent of Time Fighting. Significance was found for the Mean Percent of Time Fighting but not for the Mean Fight Scores by group. Boxplot

summary and table of counts for the Kruskal-Wallis non-parametric testing can be found in Figure 8. A table of adjusted significance is displayed in Figure 9. Statistical significance was found that the Blank-Blank compared to CBD-5-HT pairing fights for Mean Percent of Time Fighting were not the same. Finally Figure 10 displays the non-parametric box plots and summary for fight analysis based on ethogram which yielded no statistical significance. The comparison of blank/saline-blank/saline to CBD-5HT yielded statistically different distribution of mean percent time spent fighting. This correlates with the results found from the parametric testing.

Table 5 Descriptive Statistics for Paired Fight Analysis for Individual Injection Type

	Compound		Statistic	Std. Error	
Mean Fight Score	Blank	Mean	.656685	.0897042	
		95% Confidence Interval for	Lower Bound	.462891	
		Mean	Upper Bound	.850479	
		5% Trimmed Mean		.669979	
		Median		.721154	
		Variance		.113	
		Std. Deviation		.3356425	
		Minimum		.0000	
		Maximum		1.0741	
		Range		1.0741	
		Interquartile Range		.3214	
		Skewness		-1.016	.597
		Kurtosis		.474	1.154
		CBD	Mean		.761996
	95% Confidence Interval for		Lower Bound	.501502	
	Mean		Upper Bound	1.022491	
	5% Trimmed Mean			.794031	
	Median			.862534	
	Variance			.097	

		Std. Deviation	.3115887	
		Minimum	.0000	
		Maximum	.9474	
		Range	.9474	
		Interquartile Range	.1054	
		Skewness	-2.697	.752
		Kurtosis	7.442	1.481
	5HT	Mean	.720250	.0998248
		95% Confidence Interval for	Lower Bound	.484202
		Mean	Upper Bound	.956298
		5% Trimmed Mean	.718091	
		Median	.723636	
		Variance	.080	
		Std. Deviation	.2823471	
		Minimum	.2222	
		Maximum	1.2571	
		Range	1.0349	
		Interquartile Range	.1613	
		Skewness	.256	.752
		Kurtosis	2.914	1.481
Percent Time Fighting	Blank	Mean	16.381926	2.5435482
		95% Confidence Interval for	Lower Bound	10.886924
		Mean	Upper Bound	21.876927
		5% Trimmed Mean	16.187434	
		Median	17.049001	
		Variance	90.575	
		Std. Deviation	9.5170859	
		Minimum	2.0000	
		Maximum	34.2647	
		Range	32.2647	
		Interquartile Range	13.3939	
		Skewness	.394	.597
		Kurtosis	-.394	1.154
	CBD	Mean	38.122512	7.6897197
		95% Confidence Interval for	Lower Bound	19.939214
		Mean	Upper Bound	56.305809
		5% Trimmed Mean	38.120920	
		Median	33.529412	

	Variance		473.054	
	Std. Deviation		21.7498117	
	Minimum		8.6667	
	Maximum		67.6070	
	Range		58.9403	
	Interquartile Range		43.3895	
	Skewness		.143	.752
	Kurtosis		-1.184	1.481
5HT	Mean		39.327267	7.3418015
	95% Confidence Interval for	Lower Bound	21.966665	
	Mean	Upper Bound	56.687869	
	5% Trimmed Mean		39.494039	
	Median		35.368127	
	Variance		431.216	
	Std. Deviation		20.7657506	
	Minimum		8.0943	
	Maximum		67.5584	
	Range		59.4641	
	Interquartile Range		38.1281	
	Skewness		.100	.752
	Kurtosis		-.885	1.481

Figure 3 Mean Fight Score by Ethogram based on Compound Used




Figure 4 Mean Percent of Time Fighting based on Compound Used




Table 6 Descriptive For Fight Analysis based on Compound

Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean	Minimum	Maximum
------	----------------	------------	----------------------------------	---------	---------

					Lower Bound	Upper Bound		
Percent Time Fighting	Blank	16.3819 26	9.517085 9	2.543548 2	10.88692 4	21.876927	2.0000	34.2647
	CBD	38.1225 12	21.74981 17	7.689719 7	19.93921 4	56.305809	8.6667	67.6070
	5HT	39.3272 67	20.76575 06	7.341801 5	21.96666 5	56.687869	8.0943	67.5584
	Total	28.2981 73	19.68772 99	3.594471 3	20.94665 4	35.649692	2.0000	67.6070
Total Fights In First 12 mins	Blank	4.00	2.287	.611	2.68	5.32	1	8
	CBD	3.50	1.414	.500	2.32	4.68	2	6
	5HT	4.88	2.588	.915	2.71	7.04	2	9
	Total	4.10	2.171	.396	3.29	4.91	1	9
Mean Fight Score	Blank	.656685	.3356425	.0897042	.462891	.850479	.0000	1.0741
	CBD	.761996	.3115887	.1101632	.501502	1.022491	.0000	.9474
	5HT	.720250	.2823471	.0998248	.484202	.956298	.2222	1.2571
	Total	.701719	.3086335	.0563485	.586473	.816964	.0000	1.2571

Table 7 ANOVA Significance for Fight Analysis based on Compound

		Sum of Squares	df	Mean Square	F	Sig.
Percent Time Fighting	Between Groups	3733.226	2	1866.613	6.713	.004
	Within Groups	7507.369	27	278.051		
	Total	11240.595	29			
Total Fights In First 12mins	Between Groups	7.825	2	3.913	.820	.451
	Within Groups	128.875	27	4.773		
	Total	136.700	29			
Mean Fight Score	Between Groups	.060	2	.030	.301	.743
	Within Groups	2.702	27	.100		
	Total	2.762	29			

Table 8 Multiple Comparisons for Fight Analysis based on Compound

Tukey HSD

Dependent Variable	(I)	(J)	Mean	Std. Error	Sig.	95% Confidence Interval	
	CompoundN	Compoun	Difference (I-			Lower Bound	Upper
	umeric	dNumeric	J)			Bound	Bound
Percent Time Fighting	Blank	CBD	-21.7405859*	7.3903384	.018	-40.064322	-3.416850
		5HT	-22.9453412*	7.3903384	.012	-41.269077	-4.621605
	CBD	Blank	21.7405859*	7.3903384	.018	3.416850	40.064322
		5HT	-1.2047553	8.3374262	.989	-21.876717	19.467207
	5HT	Blank	22.9453412*	7.3903384	.012	4.621605	41.269077
		CBD	1.2047553	8.3374262	.989	-19.467207	21.876717
Total Fights In First 12 mins	Blank	CBD	.500	.968	.864	-1.90	2.90
		5HT	-.875	.968	.643	-3.28	1.53
	CBD	Blank	-.500	.968	.864	-2.90	1.90
		5HT	-1.375	1.092	.430	-4.08	1.33
	5HT	Blank	.875	.968	.643	-1.53	3.28
		CBD	1.375	1.092	.430	-1.33	4.08
Mean Fight Score	Blank	CBD	-.1053115	.1402095	.736	-.452949	.242326
		5HT	-.0635653	.1402095	.893	-.411203	.284073
	CBD	Blank	.1053115	.1402095	.736	-.242326	.452949
		5HT	.0417462	.1581776	.962	-.350442	.433935
	5HT	Blank	.0635653	.1402095	.893	-.284073	.411203
		CBD	-.0417462	.1581776	.962	-.433935	.350442

*. The mean difference is significant at the 0.05 level.

Table 9 Case Processing Summary for Fight Analysis based on Compound Used

	Compound	Valid		Cases Missing		Total	
		N	Percent	N	Percent	N	Percent
Mean Fight Score	Blank	14	100.0%	0	0.0%	14	100.0%
	CBD	8	100.0%	0	0.0%	8	100.0%
	5HT	8	100.0%	0	0.0%	8	100.0%
Percent Time Fighting	Blank	14	100.0%	0	0.0%	14	100.0%
	CBD	8	100.0%	0	0.0%	8	100.0%
	5HT	8	100.0%	0	0.0%	8	100.0%

Table 10 Case Processing Summary for Fight Analysis when Examined by Fight Compound Pair Match Type

	FightBasedOnPairing	Valid		Cases Missing		Total	
		N	Percent	N	Percent	N	Percent
Mean Fight Score	Blank-Blank	8	100.0%	0	0.0%	8	100.0%
	Blank-CBD	6	100.0%	0	0.0%	6	100.0%
	Blank-5HT	6	100.0%	0	0.0%	6	100.0%
	CBD-5HT	10	100.0%	0	0.0%	10	100.0%
Percent Time Fighting	Blank-Blank	8	100.0%	0	0.0%	8	100.0%
	Blank-CBD	6	100.0%	0	0.0%	6	100.0%
	Blank-5HT	6	100.0%	0	0.0%	6	100.0%
	CBD-5HT	10	100.0%	0	0.0%	10	100.0%

Table 11 Descriptive Statistics for Fight Analysis by Compound Pair Match Type

	FightBasedOnPairing	Statistic	Std. Error
Mean Fight Score	Blank-Blank	Mean	.821476
		95% Confidence Interval for Lower Bound	.626232
		Mean Upper Bound	1.016719
		5% Trimmed Mean	.834561
		Median	.836120
		Variance	.055
		Std. Deviation	.2335389
		Minimum	.3333

	Maximum	1.0741	
	Range	.7407	
	Interquartile Range	.2775	
	Skewness	-1.288	.752
	Kurtosis	2.503	1.481
Blank-CBD	Mean	.663156	.1385670
	95% Confidence Interval for Lower Bound	.306958	
	Mean Upper Bound	1.019354	
	5% Trimmed Mean	.685914	
	Median	.769231	
	Variance	.115	
	Std. Deviation	.3394186	
	Minimum	.0000	
	Maximum	.9167	
	Range	.9167	
	Interquartile Range	.3720	
	Skewness	-2.009	.845
	Kurtosis	4.302	1.741
Blank-5HT	Mean	.675463	.1651737
	95% Confidence Interval for Lower Bound	.250871	
	Mean Upper Bound	1.100056	
	5% Trimmed Mean	.680673	
	Median	.686217	
	Variance	.164	
	Std. Deviation	.4045914	
	Minimum	.0000	
	Maximum	1.2571	
	Range	1.2571	
	Interquartile Range	.4552	
	Skewness	-.495	.845
	Kurtosis	2.187	1.741
CBD-5HT	Mean	.644804	.0957962
	95% Confidence Interval for Lower Bound	.428098	
	Mean Upper Bound	.861510	
	5% Trimmed Mean	.663817	
	Median	.726667	
	Variance	.092	
	Std. Deviation	.3029340	

		Minimum	.0000			
		Maximum	.9474			
		Range	.9474			
		Interquartile Range	.3610			
		Skewness	-1.442	.687		
		Kurtosis	1.334	1.334		
Percent Time Fighting	Blank-Blank	Mean	13.547899	1.9583838		
		95% Confidence Interval for	Lower Bound	8.917057		
		Mean	Upper Bound	18.178741		
		5% Trimmed Mean		13.714009		
		Median		16.745061		
		Variance		30.682		
		Std. Deviation		5.5391459		
		Minimum		5.7385		
		Maximum		18.3673		
		Range		12.6289		
		Interquartile Range		10.6705		
		Skewness		-.637	.752	
		Kurtosis		-2.042	1.481	
			Blank-CBD	Mean	23.910131	5.9498709
				95% Confidence Interval for	Lower Bound	8.615501
				Mean	Upper Bound	39.204761
		5% Trimmed Mean		24.552106		
		Median		32.352941		
		Variance		212.406		
		Std. Deviation		14.5741478		
		Minimum		2.0000		
		Maximum		34.2647		
		Range		32.2647		
		Interquartile Range		26.9338		
		Skewness		-1.040	.845	
		Kurtosis		-1.340	1.741	
	Blank-5HT	Mean	18.869403	3.6548650		
		95% Confidence Interval for	Lower Bound	9.474274		
		Mean	Upper Bound	28.264533		
		5% Trimmed Mean		18.820056		
		Median		20.542636		
		Variance		80.148		

	Std. Deviation	8.9525543	
	Minimum	8.0943	
	Maximum	30.5328	
	Range	22.4385	
	Interquartile Range	17.8279	
	Skewness	-.213	.845
	Kurtosis	-1.407	1.741
CBD-5HT	Mean	48.388479	5.9041803
	95% Confidence Interval for Lower Bound	35.032295	
	Mean Upper Bound	61.744663	
	5% Trimmed Mean	49.232394	
	Median	50.939457	
	Variance	348.593	
	Std. Deviation	18.6706576	
	Minimum	13.9795	
	Maximum	67.6070	
	Range	53.6275	
	Interquartile Range	31.7335	
	Skewness	-.557	.687
	Kurtosis	-.783	1.334

Figure 5 Mean Fight Score by Ethogram Based on Compound Pair Match Type




Figure 6 Mean Percent Time Fighting based on Compound Pair Match Type




Table 12 ANOVA Results for Fights based on Compound Pair Match Type

		Sum of Squares	df	Mean Square	F	Sig.
Mean Fight Score	Between Groups	.160	3	.053	.533	.663
	Within Groups	2.602	26	.100		
	Total	2.762	29			
Percent Time Fighting	Between Groups	6425.708	3	2141.903	11.566	.000
	Within Groups	4814.886	26	185.188		
	Total	11240.595	29			

Table 13 Multiple Comparisons for Fights based on Compound Pair Match Type

Tukey HSD

Dependent Variable	(I) FightBased OnPairing	(J) FightBased OnPairing	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
						Lower Bound	Upper Bound
Mean Fight Score	Blank- Blank	Blank-CBD	.1583193	.1708547	.791	-.310390	.627029
		Blank-5HT	.1460124	.1708547	.828	-.322697	.614722
		CBD-5HT	.1766719	.1500634	.646	-.235000	.588344
	Blank-CBD	Blank-Blank	-.1583193	.1708547	.791	-.627029	.310390
		Blank-5HT	-.0123070	.1826514	1.000	-.513378	.488764
		CBD-5HT	.0183526	.1633684	.999	-.429819	.466524
	Blank-5HT	Blank-Blank	-.1460124	.1708547	.828	-.614722	.322697
		Blank-CBD	.0123070	.1826514	1.000	-.488764	.513378
		CBD-5HT	.0306595	.1633684	.998	-.417512	.478831
CBD-5HT	Blank-Blank	-.1766719	.1500634	.646	-.588344	.235000	
	Blank-CBD	-.0183526	.1633684	.999	-.466524	.429819	
	Blank-5HT	-.0306595	.1633684	.998	-.478831	.417512	
Percent Time Fighting	Blank- Blank	Blank-CBD	-10.3622318	7.3493636	.505	-30.523887	9.799423
		Blank-5HT	-5.3215042	7.3493636	.887	-25.483159	14.840151
		CBD-5HT	-34.8405803*	6.4550200	.000	-52.548765	-17.132396
	Blank-CBD	Blank-Blank	10.3622318	7.3493636	.505	-9.799423	30.523887
		Blank-5HT	5.0407276	7.8568002	.918	-16.512988	26.594444
		CBD-5HT	-24.4783485*	7.0273357	.009	-43.756578	-5.200119
Blank-5HT	Blank-Blank	5.3215042	7.3493636	.887	-14.840151	25.483159	

	Blank-CBD	-5.0407276	7.8568002	.918	-26.594444	16.512988
	CBD-5HT	-29.5190761*	7.0273357	.001	-48.797306	-10.240846
CBD-5HT	Blank-Blank	34.8405803*	6.4550200	.000	17.132396	52.548765
	Blank-CBD	24.4783485*	7.0273357	.009	5.200119	43.756578
	Blank-5HT	29.5190761*	7.0273357	.001	10.240846	48.797306

*. The mean difference is significant at the 0.05 level.


Figure 7 Non-parametric Analysis of Time Spent Fighting By Pair Match Type

Hypothesis Test Summary

	Null Hypothesis	Test	Sig.	Decision
1	The distribution of PercentTimeFighting is the same across categories of FightBasedOnPairing.	Independent-Samples Kruskal-Wallis Test	.001	Reject the null hypothesis.
2	The distribution of MeanFightScore is the same across categories of FightBasedOnPairing.	Independent-Samples Kruskal-Wallis Test	.431	Retain the null hypothesis.

Asymptotic significances are displayed. The significance level is .05.

Figure 8 Non-parametric Boxplots for Pair-based Time Spent Fighting by Pair Match Type



Total N	30
Test Statistic	15.585
Degrees of Freedom	3
Asymptotic Sig. (2-sided test)	.001


1. The test statistic is adjusted for ties.

Figure 9 Pairwise Comparisons of Mean Percent of Time Fighting and Hypothesis Table for Non-parametric Testing by Pair Match Type

Sample1-Sample2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj.Sig.
Blank-Blank-Blank-5HT	-4.167	4.753	-.877	.381	1.000
Blank-Blank-Blank-CBD	-7.000	4.753	-1.473	.141	.845
Blank-Blank-CBD-5HT	-15.800	4.174	-3.785	.000	.001
Blank-5HT-Blank-CBD	2.833	5.081	.558	.577	1.000
Blank-5HT-CBD-5HT	-11.633	4.545	-2.560	.010	.063
Blank-CBD-CBD-5HT	-8.800	4.545	-1.936	.053	.317

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.
 Asymptotic significances (2-sided tests) are displayed. The significance level is .05.
 Significance values have been adjusted by the Bonferroni correction for multiple tests.

Figure 10 Non-Parametric Box Plots and Summary for Fight Analysis based on Ethogram Score for Pair Match Type



Total N	30
Test Statistic	2.752
Degrees of Freedom	3
Asymptotic Sig. (2-sided test)	.431

1. The test statistic is adjusted for ties.
2. Multiple comparisons are not performed because the overall test does not show significant differences across samples.

Hunger

The number analyzed for each compound type is summarized in table 14. A table of descriptive statistics (Table 15) for mean percent of food consumed based on the compound injected and concentration was generated. A boxplots was generated for the mean percent of food consumed based on compound and concentration (Figure 11). ANOVA analysis was completed (Table 16) and yielded no statistical significance for variance in percent of food consumed. The results for statistical comparison based on compound were used to create a means plot (Figure 12). No significance was found between groups for percent of food consumed.

Table 14 Case Processing Summary for Percent Food Consumed by Compound and Concentration

	Compound	Valid		Cases Missing		Total	
		N	Percent	N	Percent	N	Percent
Percent Food Consumed	Blank	16	100.0%	0	0.0%	16	100.0%
	CBD 2ug/mg	12	100.0%	0	0.0%	12	100.0%
	CBD 5ug/mg	16	100.0%	0	0.0%	16	100.0%
	5HT 5ug/mg	16	100.0%	0	0.0%	16	100.0%
	CBD 10ug/mg	16	100.0%	0	0.0%	16	100.0%

Table 15 Descriptive Statistics for Mean Percent Food Consumed by Compound and Concentration

	Compound		Statistic	Std. Error		
Percent Food Consumed	Blank	Mean	.0406	.02046		
		95% Confidence Interval for Mean	Lower Bound	-.0030		
			Upper Bound	.0842		
		5% Trimmed Mean	.0318			
		Median	.0000			
		Variance	.007			
		Std. Deviation	.08185			
		Minimum	.00			
		Maximum	.24			
		Range	.24			
		Interquartile Range	.04			
		Skewness	2.011	.564		
		Kurtosis	2.809	1.091		
		CBD 2ug/mg	CBD 2ug/mg	Mean	.0200	.00870
				95% Confidence Interval for Mean	Lower Bound	.0008
Upper Bound	.0392					
5% Trimmed Mean	.0178					
Median	.0000					
Variance	.001					
Std. Deviation	.03015					
Minimum	.00					
Maximum	.08					
Range	.08					
Interquartile Range	.05					
Skewness	1.242			.637		
Kurtosis	.001			1.232		
CBD 5ug/mg	CBD 5ug/mg			Mean	.0219	.01152
				95% Confidence Interval for Mean	Lower Bound	-.0027
		Upper Bound	.0464			
		5% Trimmed Mean	.0143			
		Median	.0000			
		Variance	.002			
		Std. Deviation	.04608			

	Minimum		.00	
	Maximum		.18	
	Range		.18	
	Interquartile Range		.02	
	Skewness		3.064	.564
	Kurtosis		10.219	1.091
5HT 5ug/mg	Mean		.0163	.00826
	95% Confidence Interval for Mean	Lower Bound	-.0014	
		Upper Bound	.0339	
	5% Trimmed Mean		.0114	
	Median		.0000	
	Variance		.001	
	Std. Deviation		.03304	
	Minimum		.00	
	Maximum		.12	
	Range		.12	
	Interquartile Range		.02	
Skewness		2.596	.564	
Kurtosis		6.734	1.091	
CBD 10ug/mg	Mean		.0050	.00438
	95% Confidence Interval for Mean	Lower Bound	-.0043	
		Upper Bound	.0143	
	5% Trimmed Mean		.0017	
	Median		.0000	
	Variance		.000	
	Std. Deviation		.01751	
	Minimum		.00	
	Maximum		.07	
	Range		.07	
	Interquartile Range		.00	
	Skewness		3.873	.564
	Kurtosis		15.213	1.091

Figure 11 Mean Percent Food Consumed base on Compound and Concentration Injected





Table 16 Multiple Comparisons For Mean Percent of Food Consumed based on Compound Used

ANOVA

PercentFoodConsumed

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	.011	4	.003	1.156	.337
Within Groups	.163	71	.002		
Total	.174	75			

Figure 12 Means Plot for Percent Food Consumed based on Compound and Concentration



Discussion

Motility

The purpose of examining motility was to determine if injections of CBD would influence the outcomes from fights by hindering movement. Part of the complex social interaction during a fight involves both postural changes and raising the claws into a meral spread (73). Immunofluorescence tagging of CB1 receptors in crayfish have been identified via microscopy (47). In addition, EPSP amplitudes were decreased at the NMJ after cannabidiol-like agent was used, suggesting that CBD would down regulate AP frequency at the muscular junction (67,69). Our research demonstrated a general decrease in movement after CBD injections compared to VH saline controls (i.e. blanks). However, no statistical significance was found overall indicating that movement was not inhibited or promoted from injections of CBD when compared against VH saline controls. The number of trials was relatively small though, with only 6 VH saline injections and 8 CBD injections completed. A larger sample may help to indicate overall reductions in motility. In addition, only one high concentrated dose of 10ug/g was administered due to time constraints brought on by COVID-19. Future trials could be completed using a range of doses. Perhaps a better indicator of influence of the NMJ would be trials based on treadmill activity or food seeking behavior where more time would be spent purposefully in movement rather than passively exploring. For the purpose of this project, the goal from motility analysis was to determine if CBD interacted with the NMJ enough to influence the interaction for dominance with competing crayfish. Based on the above results, the change in movement was not significant enough to inhibit or influence the outcome of a fight at the doses administered.

Fights

The two main ways fight interactions were analyzed involved a mean behavioral ethogram score of aggression (Table 1), and mean percent of time spent fighting. Serotonin has been shown to directly influence tail-flip response in crayfish (58). The decreased EPSP at the Lateral Giant (LG) neuron via increased synaptic 5-HT directly influenced behavior (61,62). CBD has been known to act on 5-HT receptors in mammalian models (74). It was postulated that if CBD interacted with the LG neuron of the tail tissue influencing fights that the measured value for the ethogram score would increase. However, this was not observed when compared against all other groups. Video analysis of fights included ethogram ranking, tail-flip counts, percent of time interacting in a fight, total number of interactions during the initial 12 minutes of recording, and if a crayfish died during the fight. Only two areas, mean ethogram rank and mean percent of time fighting based on pairs, were noted for any significance of frequency and were pursued for statistical significance. No significance was observed for the ethogram ranking using parametric and non-parametric tests. However, the analysis of mean percent time fighting based on injection pairing types yielded significance for both parametric and non-parametric tests. Specifically VH saline control-control pairs compared to CBD-5-HT pairs indicated that the means were statistically different with a p-value of 0.001 using Kruskal-Wallis analysis. Blank-Saline control pairs had a mean of 13.54% compared to 48.39% for CBD-5HT pairs. This influence is postulated to be from CBD binding to the 5-HT₁ receptors on the LG neuron acting as an agonist, thus inhibiting the EPSP for tail-flip retreat behavior and increasing aggressive posturing and meral spread. The CBD could act two fold by both activating the 5-HT_{1A} receptors as well as increasing synaptic serotonin that would otherwise bind to the respective receptors. The significance found for CBD influencing fights was concluded with a concentration of 2 ug/g as

compared to the 5ug/g 5-HT. If the U-shaped curve observed with most pharmacological agents is applied to CBD then the optimal concentration could be different from what was used for testing. This means that the significant difference observed could be amplified with the proper dosage. General observation of the fights indicated that 5-HT produced aggressive fight behaviors such as curved tail postures, meral spread, and rapid pursuit of opponents. CBD produced a passive, responsive behavior to pursuers where fights were not sought out as quickly as with 5-HT. A meral spread (raised claws) and curved posture were still produced when opponents approached CBD crayfish. However, once engaged in a fight CBD crayfish appeared to retreat less frequently than VH saline injected crayfish. This would explain the relative similarity in ethogram ranking and the increase in percent of time spent engaged in combat. These observations were anecdotal and therefore not accurately measured behaviors and the validity remains unknown. Review of raw data indicated that the number of ethogram rankings of 1 (pursuing opponent) were scattered and no clear pattern emerged using this method. Additional video analysis could be conducted with a reconstructed ethogram to observe only pursuit behavior. The fights were completed with a low number of trials as three of the four main injection types were conducted with only 6 paired fights. Additional pairings would increase the power of the analysis. These pairings could include CBD-CBD and 5-HT-5-HT compound matching to better assess the fight outcomes. For this study, the significance found for mean percent of time fighting builds on previous postulations that CBD would influence the tail-flip response to retreat from fights and indicates a relationship between cannabinoids and crayfish behavior.

Hunger

Food seeking behavior was addressed extensively with a range of CBD concentrations. The purpose was to explore the possibility that cannabinoids could influence various receptors throughout the nervous system of crayfish, including the 5-HT subtypes found throughout the eye-stalks and central nervous system (55). These receptors line the digestive system of crayfish as well and could result in alterations in hunger if stimulated. However, after extensive analysis at multiple concentrations statistical significance was not found for CBD injections changing the amount of food consumed as compared to blank-saline controls or 5-HT injections. This may be due to the injury incurred during the injection process, as all animals exhibited the same lack of hunger despite being deprived of food prior to testing. To properly address the potential that injury influences the drive for food, alternative drug delivery methods could be employed, such as the placement of a capillary tube and/or using an injection pump after the injection site heals. In addition, a Y-maze could be utilized to further address a drive to pursue food over an extended period of time. For the purpose of this analysis, no observed behavioral changes occurred after injections of CBD to influence amount of food consumed.

Conclusion

To date, no trials have been published that involved cannabinoids and behavior analysis of crayfish. This project is the first step towards understanding how the simpler nervous system of crayfish utilizes cannabidiol with serotonin receptors. While no significance was found for CBD influencing motility and hunger, it was determined that there is a significant difference in mean time spent fighting when paired. This significance is postulated to be from activation of 5-HT_{1A} receptors. These receptors in humans are influenced by SSRIs to treat a variety of mental disorders such as anxiety and depression. SSRIs come with extensive side effects and that can partially decrease the quality of life and alter behaviors. The side effects from CBD are minimal when compared to SSRIs. However the effects of CBD, specifically in simple neurological models, has not been well studied. Yet, cannabis has gained wide-legalization across the US resulting in an increase in consumption of cannabinoids such as CBD. Further studies in crayfish and elsewhere should be completed to support the proper uses and dangers of cannabidiol within an unregulated market.

References

1. Soni A. The five most costly conditions, 1996 and 2006: Estimates for the US civilian noninstitutionalized population. Statistical Brief# 248. July 2009. Agency Healthc Res Qual Rockv MD. 2009;
2. Bloom DE, Cafiero E, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, et al. The Global Economic Burden of Noncommunicable Diseases [Internet]. Program on the Global Demography of Aging; 2012 Jan [cited 2018 Feb 9]. (PGDA Working Papers). Report No.: 8712. Available from: <https://ideas.repec.org/p/gdm/wpaper/8712.html>
3. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. *Dialogues Clin Neurosci*. 2015 Sep;17(3):327–35.
4. Schomerus G, Matschinger H, Angermeyer MC. Alcoholism: Illness beliefs and resource allocation preferences of the public. *Drug Alcohol Depend*. 2006 May 20;82(3):204–10.
5. Trautmann S, Rehm J, Wittchen H. The economic costs of mental disorders. *EMBO Rep*. 2016 Sep;17(9):1245–9.
6. Somers JM, Goldner EM, Waraich P, Hsu L. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. *Can J Psychiatry Rev Can Psychiatr*. 2006 Feb;51(2):100–13.
7. Merikangas KR, He J, Burstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime Prevalence of Mental Disorders in US Adolescents: Results from the National Comorbidity Study-Adolescent Supplement (NCS-A). *J Am Acad Child Adolesc Psychiatry*. 2010 Oct;49(10):980–9.
8. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, Severity, and Comorbidity of Twelve-month DSM-IV Disorders in the National Comorbidity Survey Replication (NCS-R). *Arch Gen Psychiatry*. 2005 Jun;62(6):617–27.
9. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. *Depress Anxiety*. 2000;12 Suppl 1:2–19.
10. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: Serotonin receptors and pathways mediate therapeutic effects and side effects. *J Affect Disord*. 1998 Dec 1;51(3):215–35.
11. Politis M, Niccolini F. Serotonin in Parkinson's disease. *Behav Brain Res*. 2015 Jan;277:136–45.
12. Muller CP, Cunningham KA. Handbook of the Behavioral Neurobiology of Serotonin [Internet]. Elsevier Science; 2020. (ISSN). Available from: https://books.google.com/books?id=f_zLDwAAQBAJ
13. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, et al. Reduced Serotonin Type 1A Receptor Binding in Panic Disorder. *J Neurosci*. 2004 Jan 21;24(3):589–91.
14. Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien L-K, et al. Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder. *Biol Psychiatry*. 2007 May 1;61(9):1081–9.
15. Savitz J, Lucki I, Drevets WC. 5-HT1A receptor function in major depressive disorder. *Prog Neurobiol*. 2009 May 1;88(1):17–31.

16. Garcia-Garcia A, Tancredi AN-, Leonardo ED. 5-HT_{1A} receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function. *Psychopharmacology (Berl)*. 2014 Feb;231(4):623–36.
17. Ansorge MS, Morelli E, Gingrich JA. Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. *J Neurosci Off J Soc Neurosci*. 2008 Jan 2;28(1):199–207.
18. Hannon J, Hoyer D. Molecular biology of 5-HT receptors. *Behav Brain Res*. 2008 Dec 16;195(1):198–213.
19. Akimova E, Lanzenberger R, Kasper S. The Serotonin-1A Receptor in Anxiety Disorders. *Biol Psychiatry*. 2009 Oct 1;66(7):627–35.
20. Jankovic J. Parkinson’s disease tremors and serotonin. *Brain*. 2018 Mar 1;141(3):624–6.
21. Gordon JA, Hen R. The serotonergic system and anxiety. *NeuroMolecular Med*. 2004 Feb 1;5(1):27–40.
22. Davidson JRT. Pharmacotherapy of Generalized Anxiety Disorder. *J Clin Psychiatry*. 2001 Sep 1;62(suppl 11):46–50.
23. Blanco C, Antia SX, Liebowitz MR. Pharmacotherapy of social anxiety disorder. *Biol Psychiatry*. 2002 Jan 1;51(1):109–20.
24. Ganasen KA, Stein DJ. Pharmacotherapy of Social Anxiety Disorder. In: *Behavioral Neurobiology of Anxiety and Its Treatment [Internet]*. Springer, Berlin, Heidelberg; 2009 [cited 2018 Feb 20]. p. 487–503. (Current Topics in Behavioral Neurosciences). Available from: https://link.springer.com/chapter/10.1007/7854_2009_1
25. Hervás I, Queiroz CMT, Adell A, Artigas F. Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat. *Br J Pharmacol*. 2000 May;130(1):160–6.
26. *Cleveland Clinic Journal of Medicine*. 2006 April;73:351-361. Side effects of antidepressants: An overview [Internet]. [cited 2018 Feb 21]. Available from: <https://www.mdedge.com/ccjm/article/94516/drug-therapy/side-effects-antidepressants-overview>
27. Bet PM, Hugtenburg JG, Penninx BWJH, Hoogendijk WJG. Side effects of antidepressants during long-term use in a naturalistic setting. *Eur Neuropsychopharmacol*. 2013 Nov 1;23(11):1443–51.
28. Cascade E, Kalali AH, Kennedy SH. Real-World Data on SSRI Antidepressant Side Effects. *Psychiatry Edgmont*. 2009 Feb;6(2):16–8.
29. Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. *J Clin Psychiatry*. 2004 Jul;65(7):959–65.
30. Damsa C, Bumb A, Bianchi-Demicheli F, Vidailhet P, Sterck R, Andreoli A, et al. “Dopamine-Dependent” Side Effects of Selective Serotonin Reuptake Inhibitors: A Clinical Review. *J Clin Psychiatry*. 2004 Aug 16;65(8):1064–8.

31. Scharf EL. Translating Endocannabinoid Biology into Clinical Practice: Cannabidiol for Stroke Prevention. *Cannabis Cannabinoid Res.* 2017 Oct;2(1):259–64.
32. Rajesh M, Mukhopadhyay P, Bátkai S, Haskó G, Liaudet L, Drel VR, et al. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. *Am J Physiol - Heart Circ Physiol.* 2007 Jul 1;293(1):H610–9.
33. Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, Filippis DD, et al. Cannabidiol Reduces A β -Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPAR γ Involvement. *PLOS ONE.* 2011 Dec 5;6(12):e28668.
34. Durst R, Danenberg H, Gallily R, Mechoulam R, Meir K, Grad E, et al. Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. *Am J Physiol - Heart Circ Physiol.* 2007 Dec 1;293(6):H3602–7.
35. Rock EM, Sticht MA, Limebeer CL, Parker LA. Cannabinoid Regulation of Acute and Anticipatory Nausea. *Cannabis Cannabinoid Res.* 2016 Apr;1(1):113–21.
36. Mikuriya TH. Marijuana in medicine: past, present and future. *Calif Med.* 1969 Jan;110(1):34–40.
37. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. *Neuropharmacology.* 2004 Jan 1;47(Supplement 1):345–58.
38. Iffland K, Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. *Cannabis Cannabinoid Res.* 2017;2(1):139–54.
39. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by Δ 9-THC in normal subjects. *Psychopharmacology (Berl).* 1982;76(3):245–250.
40. Zuardi AW, Crippa J a. S, Hallak JEC, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. *Braz J Med Biol Res.* 2006 Apr;39(4):421–9.
41. Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. *Psychopharmacology (Berl).* 1990 Apr 1;100(4):558–9.
42. Moreira FA, Aguiar DC, Guimarães FS. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. *Prog Neuropsychopharmacol Biol Psychiatry.* 2006 Dec 30;30(8):1466–71.
43. Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimarães FS, et al. Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life. *Front Pharmacol [Internet].* 2017 May 11 [cited 2017 Dec 6];8. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425583/>
44. Arndt DL, de Wit H. Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults. *Cannabis Cannabinoid Res.* 2017 Jun;2(1):105–13.
45. Campos AC, Guimarães FS. Involvement of 5HT_{1A} receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. *Psychopharmacology (Berl).* 2008 Aug 1;199(2):223.

46. Morales M, Bäckman C. Coexistence of serotonin 3 (5-HT₃) and CB1 cannabinoid receptors in interneurons of hippocampus and dentate gyrus. *Hippocampus*. 2002 Jan 1;12(6):756–64.
47. Sahel MH, Garcia LM, Truong NM. Identifying CB 1 Receptors in the crayfish neuromuscular junction through immunofluorescence staining. *Pioneer Neurosci*. 2007;8:13–16.
48. Green S, Newman Z, Nordquist S. Pharmacological evidence for cannabinoid receptors in glutamatergic synapses at the crayfish neuromuscular junction. *Pioneer Neurosci*. 2005;6:55–61.
49. Huber R, Panksepp JB, Nathaniel T, Alcaro A, Panksepp J. Drug-sensitive reward in crayfish: An invertebrate model system for the study of SEEKING, reward, addiction, and withdrawal. *Neurosci Biobehav Rev*. 2011 Oct;35(9):1847–53.
50. Nathaniel TI, Huber R, Panksepp J. Repeated cocaine treatments induce distinct locomotor effects in Crayfish. *Brain Res Bull*. 2012 Feb;87(2–3):328–33.
51. Imeh-Nathaniel A, Rincon N, Orfanakos VB, Brechtel L, Wormack L, Richardson E, et al. Effects of chronic cocaine, morphine and methamphetamine on the mobility, immobility and stereotyped behaviors in crayfish. *Behav Brain Res*. 2017 Aug;332:120–5.
52. Shipley AT, Imeh-Nathaniel A, Orfanakos VB, Wormack LN, Huber R, Nathaniel TI. The Sensitivity of the Crayfish Reward System to Mammalian Drugs of Abuse. *Front Physiol* [Internet]. 2017 [cited 2018 Jan 13];8. Available from: <https://www.frontiersin.org/articles/10.3389/fphys.2017.01007/full>
53. Tabor JN, Cooper RL. Physiologically identified 5-HT₂-like receptors at the crayfish neuromuscular junction. *Brain Res*. 2002 Apr 5;932(1):91–8.
54. Calderón-Rosete G, Flores G, Rodríguez-Sosa L. Diurnal rhythm in the levels of the serotonin 5-HT_{1A} receptors in the crayfish eyestalk. *Synapse*. 2006 May 1;59(6):368–73.
55. Spitzer N, Edwards DH, Baro DJ. Conservation of structure, signaling and pharmacology between two serotonin receptor subtypes from decapod crustaceans, *Panulirus interruptus* and *Procambarus clarkii*. *J Exp Biol*. 2008 Jan 1;211(1):92–105.
56. Fossat P, Bacqué-Cazenave J, Deurwaerdère PD, Delbecque J-P, Cattaert D. Anxiety-like behavior in crayfish is controlled by serotonin. *Science*. 2014 Jun 13;344(6189):1293–7.
57. Huber R, Panksepp JB, Yue Z, Delago A, Moore P. Dynamic Interactions of Behavior and Amine Neurochemistry in Acquisition and Maintenance of Social Rank in Crayfish. *Brain Behav Evol*. 2001 May;57(5):271–82.
58. Panksepp JB, Yue Z, Drerup C, Huber R. Amine neurochemistry and aggression in crayfish. *Microsc Res Tech*. 2003 Feb 15;60(3):360–8.
59. Krasne FB, Wine JJ. The Production of Crayfish Tailflip Escape Responses. In: *Neural Mechanisms of Startle Behavior* [Internet]. Springer, Boston, MA; 1984 [cited 2018 Mar 4]. p. 179–211. Available from: https://link.springer.com/chapter/10.1007/978-1-4899-2286-1_7
60. Glanzman DL, Krasne FB. 5, 7-Dihydroxytryptamine lesions of crayfish serotonin-containing neurons: effect on the lateral giant escape reaction. *J Neurosci*. 1986;6(6):1560–1569.

61. Glanzman DL, Krasne FB. Serotonin and octopamine have opposite modulatory effects on the crayfish's lateral giant escape reaction. *J Neurosci Off J Soc Neurosci*. 1983 Nov;3(11):2263–9.
62. Vu ET, Lee SC, Krasne FB. The mechanism of tonic inhibition of crayfish escape behavior: distal inhibition and its functional significance. *J Neurosci Off J Soc Neurosci*. 1993 Oct;13(10):4379–93.
63. Real D, Czternasty G. Mapping of serotonin-like immunoreactivity in the ventral nerve cord of crayfish. *Brain Res*. 1990 Jun 25;521(1–2):203–12.
64. Yeh S-R, Fricke RA, Edwards DH. The effect of social experience on serotonergic modulation of the escape circuit of crayfish. *Sci Wash*. 1996 Jan 19;271(5247):366.
65. Huber R, Smith K, Delago A, Isaksson K, Kravitz EA. Serotonin and aggressive motivation in crustaceans: altering the decision to retreat. *Proc Natl Acad Sci*. 1997;94(11):5939–5942.
66. Huber R, Delago A. Serotonin alters decisions to withdraw in fighting crayfish, *Astacus astacus*: the motivational concept revisited. *J Comp Physiol A*. 1998 Apr 1;182(5):573–83.
67. Graves A, McCarthy K, Mudoh E. Increased EPSP amplitude at the crayfish neuromuscular junction for acute but not chronic exposure to fluoxetine. *Pioneer Neurosci*. 2013 Jan 11;3:49–52.
68. Di Carlo G, Borrelli F, Ernst E, Izzo AA. St John's wort: Prozac from the plant kingdom. *Trends Pharmacol Sci*. 2001 Jun 1;22(6):292–7.
69. Evans S, Kljaich J. The effect of endocannabinoids at the crayfish neuromuscular junction. *Pioneer Neurosci*. 2010;10:59–62.
70. Bergman DA, Kozlowski CP, McIntyre JC, Huber R, Daws AG, Moore PA. Temporal dynamics and communication of winner-effects in the crayfish, *orconectes rusticus*. *Behaviour*. 2003 Jun 1;140(6):805–25.
71. Tierney A, Mangiamele L. Effects of serotonin and serotonin analogs on posture and agonistic behavior in crayfish. *J Comp Physiol A*. 2001 Dec 1;187(10):757–67.
72. Tierney AJ. Structure and function of invertebrate 5-HT receptors: a review. *Comp Biochem Physiol A Mol Integr Physiol*. 2001 Apr;128(4):791–804.
73. Livingstone MS, Harris-Warrick RM, Kravitz EA. Serotonin and octopamine produce opposite postures in lobsters. *Science*. 1980 Apr 4;208(4439):76–9.
74. Scharf EL. Translating Endocannabinoid Biology into Clinical Practice: Cannabidiol for Stroke Prevention. *Cannabis Cannabinoid Res*. 2017 Oct;2(1):259–64.